Provided by Tiger Fintech (Singapore) Pte. Ltd.

Erasca, Inc.

1.40
+0.03502.56%
Post-market: 1.400.00000.00%16:04 EDT
Volume:645.55K
Turnover:905.66K
Market Cap:396.60M
PE:-2.37
High:1.43
Open:1.35
Low:1.31
Close:1.37
Loading ...

Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors

MT Newswires Live
·
02 Jun

Erasca Inc - Initial Phase 1 Data for Ras-Targeting Programs Expected in 2026

THOMSON REUTERS
·
02 Jun

Erasca Announces Ind Clearance for Potential First-in-Class and Best-in-Class Pan-Kras Inhibitor Eras-4001

THOMSON REUTERS
·
02 Jun

Erasca’s Strategic Advancements and Promising RAS-Targeting Therapies Justify Buy Rating

TIPRANKS
·
14 May

Erasca Inc : Guggenheim Cuts Target Price to $3 From $3.5

THOMSON REUTERS
·
14 May

Erasca reports Q1 EPS (11c), consensus (13c)

TIPRANKS
·
14 May

Erasca Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Erasca Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
14 May

Erasca Q1 EPS $(0.11) Beats $(0.12) Estimate

Benzinga
·
14 May

Erasca Inc. Reports Q1 2025 Results: Net Loss Narrows to $31M, EPS Improves to $(0.11)

Reuters
·
14 May

BRIEF-Erasca Q1 Basic EPS USD -0.11

Reuters
·
14 May

Erasca Inc: Cash Runway Guidance Extended to H2 2028

THOMSON REUTERS
·
14 May

Erasca Seeks Partner for Naporafenib to Extend Cash Runway

MT Newswires Live
·
13 May

Erasca Inc: Ind Cleared for Pan-Ras Molecular Glue Eras-0015 and Ind Submitted for Pan-Kras Inhibitor Eras-4001

THOMSON REUTERS
·
13 May

Erasca Inc: Phase 1 Monotherapy Data for Eras-0015 & Eras-4001 Expected in 2026

THOMSON REUTERS
·
13 May

Erasca Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
10 May

Erasca Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
07 May

Erasca Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
03 May

Erasca Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Apr

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

GlobeNewswire
·
30 Apr